SureTrader Advertisement PRTC
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: Peaser, conix, $Pistol Pete$
Search This Board:
Last Post: 5/5/2016 1:40:51 PM - Followers: 349 - Board type: Free - Posts Today: 0


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: MannKind Corporation to Present at the Bank of America Merrill Lynch 2016 Health Care Conference 05/05/2016 05:00:00 PM
MNKD News: Current Report Filing (8-k) 05/04/2016 05:33:47 PM
MNKD News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 05/04/2016 05:28:33 PM
MNKD News: MannKind Corporation to Hold 2016 First Quarter Financial Results Conference Call on May 9, 2016 05/02/2016 05:00:00 PM
MNKD News: Notice of Effectiveness (effect) 04/28/2016 06:01:26 AM
News News Alert: MannKind Corporation to Present at the Bank of America Merrill Lynch 2016 Health Care Conference 05/05/2016 05:00:00 PM
#18310  Sticky Note MNKD Short Interest coming down.... conix 04/25/16 03:28:02 PM
#17438  Sticky Note MNKD Manipulation Story: Peaser 02/01/16 09:03:36 AM
#16574  Sticky Note $MNKD ~ MannKind Corp. due diligence report $Pistol Pete$ 12/18/15 01:14:52 AM
#18341   Do you think the new 75 AFREZZA REPS TREND1 05/05/16 01:40:51 PM
#18340   They're not...only renewing the ATM. See company's Facebook Impailer 05/05/16 12:45:48 PM
#18339   So why is MNKD trying to sell $50 TREND1 05/05/16 09:59:38 AM
#18338   ROBIN SIMPLE ! Just go to any drug TREND1 05/05/16 09:42:23 AM
#18337   how do we prove this message robin 05/05/16 09:25:31 AM
#18336   What we need is a CC that sounds tyfoidhana 05/03/16 07:37:33 PM
#18335   Took it down and NO volume and then Hypi 05/03/16 04:11:41 PM
#18334   agree WHS 05/03/16 08:55:05 AM
#18333   I have to agree with md1225 aa we Hypi 05/03/16 07:54:05 AM
#18332   And none seem to come true! leslunier 05/02/16 04:51:32 PM
#18331   MD1225 You make many predictions. TREND1 05/02/16 03:13:31 PM
#18330   Regional partner with 100m upfront payment. US is md1225 05/02/16 02:55:38 PM
#18329   Partners cause dilution of profits and loss of control. TREND1 05/02/16 11:57:15 AM
#18328   Stay patient longs partner news is literally days md1225 05/02/16 09:08:16 AM
#18325   Mismanagement, dilution, delays... Add uncertainty. Recipe for failure! Twister 04/28/16 11:58:28 AM
#18324   Agreed. In an ideal world, the quality esedu 04/28/16 08:25:37 AM
#18323   Stocks short interest went from 120+M shares short Hypi 04/27/16 12:04:58 PM
#18322   500M shelf filing should sustain the company for biginvestors 04/27/16 08:55:07 AM
#18321   Interesting Conference Call and 8-K today: Southbird66 04/27/16 12:13:42 AM
#18320   We still have one big question. IMHO. TREND1 04/26/16 07:29:35 PM
#18319   This new marketing guy talked to the ENDO'S TREND1 04/26/16 06:30:19 PM
#18318   Very good conference call. IMHO. TREND1 04/26/16 05:45:30 PM
#18316   Did someone say it was...halted? G3TCRUNK3R 04/26/16 04:30:13 PM
#18315   I am not a moderator. See top of board. TREND1 04/26/16 12:07:07 PM
#18313   TREND1 = 2 POSTINGS TREND1 04/26/16 11:24:48 AM
#18311   I said this weekend I expected one more Hypi 04/25/16 04:09:14 PM
#18310   MNKD Short Interest coming down.... conix 04/25/16 03:28:02 PM
#18309   One thing you can say for MNKD is conix 04/25/16 03:24:04 PM
#18308   Sanfran baby everything is double! Except housing that's md1225 04/25/16 11:04:13 AM
#18307   Final piece of type 1 diabetes puzzle solved TREND1 04/25/16 10:24:25 AM
#18306   Kaiser hospital San Francisco Bay area nursing salary TREND1 04/25/16 09:11:48 AM
#18305   RN average national salary 58k. md1225 04/25/16 06:27:49 AM
#18304   FDA Commissioner who railroaded MNKD over the years Hypi 04/25/16 03:23:05 AM
#18303   My real question "will the establishment that runs Hypi 04/24/16 11:48:45 PM
#18302   MN1225 Hopefully MNKD learned one thing from SNY partnership. TREND1 04/24/16 10:05:52 PM
#18301   Hypi don't forget suitor number 2/3/4 all called md1225 04/24/16 07:45:00 PM
#18300   Well it is unusual because in the past Hypi 04/24/16 10:24:45 AM
#18299   Past two days have had the lowest volume tyfoidhana 04/24/16 09:29:06 AM
#18298   thanks for your answer. TREND1 04/23/16 01:24:34 PM
#18297   I am not smart enough to know the martind18 04/23/16 12:54:36 PM
#18296   MNKD WEEKLY TREND1 04/23/16 12:32:08 PM
#18295   Do you think they should get another partner ? TREND1 04/23/16 12:28:35 PM
#18294   THANKS for your reply. TREND1 04/23/16 12:25:22 PM
#18293   I sold because I figured it was dropping.... martind18 04/23/16 12:08:02 PM
#18292   He is.... Yes. Loves it. martind18 04/23/16 12:05:58 PM
#18291   martind18 Why did you sell MNKD ? TREND1 04/23/16 11:57:09 AM
#18290   maetind18 Is your DAD still on AFREZZA ? TREND1 04/23/16 11:54:30 AM
#18289   Matt addressed that already it's because they only md1225 04/23/16 11:53:23 AM
#18288   A trade above 2.24 would be very bullish. IMHO. TREND1 04/23/16 11:50:11 AM
#18287   I think those that did not renew were Hypi 04/23/16 11:24:49 AM